Overview

ANAVEX2-73 Study in Parkinson's Disease Dementia

Status:
Completed

Trial end date:
2020-09-30

Target enrollment:

Participant gender:

Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Phase:

Phase 2

Details

Lead Sponsor:

Anavex Life Sciences Corp.

Collaborator:

Anavex Germany GmbH